8158 — China Regenerative Medicine International Cashflow Statement
0.000.00%
- HK$50.20m
- HK$97.06m
- HK$69.49m
Annual cashflow statement for China Regenerative Medicine International, fiscal year end - December 31st, HKD millions except per share, conversion factor applied.
2019 December 31st | C2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | HKAS | HKAS | HKAS | HKAS | HKAS |
Status: | Final | Final | Final | Final | Final |
Net Income/Starting Line | -457 | -142 | 64.3 | 8.27 | -108 |
Depreciation | |||||
Amortisation | |||||
Non-Cash Items | 265 | -137 | -41.2 | 8.06 | 84 |
Discontinued Operations | |||||
Unusual Items | |||||
Other Non-Cash Items | |||||
Changes in Working Capital | 117 | -122 | -26.2 | -34.1 | 18.8 |
Change in Accounts Receivable | |||||
Change in Inventories | |||||
Change in Other Assets | |||||
Change in Accounts Payable | |||||
Change in Accrued Expenses | |||||
Change in Other Liabilities | |||||
Other Operating Cash Flow | |||||
Cash from Operating Activities | -23.3 | -399 | -3.02 | -17.7 | 6.34 |
Capital Expenditures | -5.74 | 0 | -0.809 | -2.59 | -0.274 |
Purchase of Fixed Assets | |||||
Purchase / Acquisition of Intangibles | |||||
Other Investing Cash Flow Items | 413 | 327 | 10.1 | 0.001 | 0.012 |
Acquisition of Business | |||||
Sale of Business | |||||
Sale of Fixed Assets | |||||
Sale/Maturity of Investment | |||||
Other Investing Cash Flow | |||||
Cash from Investing Activities | 407 | 327 | 9.27 | -2.59 | -0.262 |
Financing Cash Flow Items | -3.69 | 29.7 | -0.174 | 0 | — |
Other Financing Cash Flow | |||||
Net Issuance / Retirement of Stock | |||||
Net Issuance / Retirement of Debt | |||||
Cash from Financing Activities | -394 | 67.4 | -1.39 | 7.32 | -7.36 |
Foreign Exchange Effects | |||||
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | -10.8 | -4.52 | 5.16 | -8.08 | 1.49 |